{'output': [['Momenta Pharmaceuticals Inc', 'COMP', 'Plan', 'Trial', 'EVENT'], ['Mylan NV', 'COMP', 'Plan', 'Trial', 'EVENT'], ['Regeneron Pharmaceuticals Inc', 'COMP', 'Has', 'Eylea', 'PRODUCT'], ['Momenta Pharmaceuticals Inc', 'COMP', 'Operate_In', 'Biotechnology Industry', 'SECTOR'], ['Mylan NV', 'COMP', 'Operate_In', 'Pharmaceutical Industry', 'SECTOR'], ['Formycon AG', 'COMP', 'Develop', 'Biosimilar', 'PRODUCT'], ['Eylea', 'PRODUCT', 'Treat', 'Wet Age-Related Macular Degeneration', 'CONCEPT'], ['Eylea', 'PRODUCT', 'Treat', 'Related Eye Conditions', 'CONCEPT'], ['Regeneron Pharmaceuticals Inc', 'COMP', 'Control', 'US Patent Protection', 'ORG/REG'], ['Eylea', 'PRODUCT', 'Generate', 'Most of Regeneronâ€™s Revenue', 'ECON_INDICATOR'], ['Regeneron Pharmaceuticals Inc', 'COMP', 'Share_Price_Fell', '388', 'ECON_INDICATOR'], ['Momenta Pharmaceuticals Inc', 'COMP', 'Share_Price_Rose', '15', 'ECON_INDICATOR'], ['Mylan NV', 'COMP', 'Share_Price_Unchanged', '43.14', 'ECON_INDICATOR'], ['Eylea', 'PRODUCT', 'US Sales_Rose', '12%', 'ECON_INDICATOR'], ['Eylea', 'PRODUCT', 'Sales_Outside_US_Rose', '20%', 'ECON_INDICATOR'], ['Eylea', 'PRODUCT', 'Global Sales_Exceeded', '5 Billion', 'ECON_INDICATOR'], ['M710', 'PRODUCT', 'Proposed_Trial', 'Patients with Diabetic Macular Edema', 'CONCEPT'], ['M710', 'PRODUCT', 'Compare', 'Eylea', 'PRODUCT'], ['M710', 'PRODUCT', 'Prove', 'Close Enough', 'CONCEPT'], ['M710', 'PRODUCT', 'Satisfy', 'Regulators', 'ORG/REG']]}